Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin

Keishi Yamasaki, Taisuke Enokida, Kazuaki Taguchi, Shigeyuki Miyamura, Akito Kawai, Shuichi Miyamoto, Toru Maruyama, Hakaru Seo, Masaki Otagiri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sodium 4-phenylbutyrate (PB) is clinically used as a drug for treating urea cycle disorders. Recent research has shown that PB also has other pharmacologic activities, suggesting that it has the potential for use as a drug for treating other disorders. In the process of drug development, preclinical testing using experimental animals is necessary to verify the efficacy and safety of PB. Although the binding of PB to human albumin has been studied, our knowledge of its binding to albumin from the other animal species is extremely limited. To address this issue, we characterized the binding of PB to albumin from several species (human, bovine, rabbit, and rat). The results indicated that PB interacts with 1 high-affinity site of albumin from these species, which corresponds to site II of human albumin. The affinities of PB to human and bovine albumins were higher than those to rabbit and rat albumin, and that to rabbit albumin was the lowest. Binding and molecular docking studies using structurally related compounds of PB suggested that species differences in the affinity are attributed to differences in the structural feature of the PB-binding sites on albumins (e.g., charge distribution, hydrophobicity, shape, or size).

Original languageEnglish
Pages (from-to)2860-2867
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume106
Issue number9
DOIs
Publication statusPublished - 2017 Sep 1
Externally publishedYes

Fingerprint

Serum Albumin
Albumins
Rabbits
Inborn Urea Cycle Disorder
Pharmaceutical Preparations
4-phenylbutyric acid
Hydrophobic and Hydrophilic Interactions
Binding Sites
Safety
Research

Keywords

  • albumin
  • distribution
  • molecular modeling
  • protein binding
  • protein structure

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Yamasaki, K., Enokida, T., Taguchi, K., Miyamura, S., Kawai, A., Miyamoto, S., ... Otagiri, M. (2017). Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. Journal of Pharmaceutical Sciences, 106(9), 2860-2867. https://doi.org/10.1016/j.xphs.2017.04.025

Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. / Yamasaki, Keishi; Enokida, Taisuke; Taguchi, Kazuaki; Miyamura, Shigeyuki; Kawai, Akito; Miyamoto, Shuichi; Maruyama, Toru; Seo, Hakaru; Otagiri, Masaki.

In: Journal of Pharmaceutical Sciences, Vol. 106, No. 9, 01.09.2017, p. 2860-2867.

Research output: Contribution to journalArticle

Yamasaki, K, Enokida, T, Taguchi, K, Miyamura, S, Kawai, A, Miyamoto, S, Maruyama, T, Seo, H & Otagiri, M 2017, 'Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin', Journal of Pharmaceutical Sciences, vol. 106, no. 9, pp. 2860-2867. https://doi.org/10.1016/j.xphs.2017.04.025
Yamasaki K, Enokida T, Taguchi K, Miyamura S, Kawai A, Miyamoto S et al. Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. Journal of Pharmaceutical Sciences. 2017 Sep 1;106(9):2860-2867. https://doi.org/10.1016/j.xphs.2017.04.025
Yamasaki, Keishi ; Enokida, Taisuke ; Taguchi, Kazuaki ; Miyamura, Shigeyuki ; Kawai, Akito ; Miyamoto, Shuichi ; Maruyama, Toru ; Seo, Hakaru ; Otagiri, Masaki. / Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. In: Journal of Pharmaceutical Sciences. 2017 ; Vol. 106, No. 9. pp. 2860-2867.
@article{6de98257c13a4123b5693619f6bde32b,
title = "Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin",
abstract = "Sodium 4-phenylbutyrate (PB) is clinically used as a drug for treating urea cycle disorders. Recent research has shown that PB also has other pharmacologic activities, suggesting that it has the potential for use as a drug for treating other disorders. In the process of drug development, preclinical testing using experimental animals is necessary to verify the efficacy and safety of PB. Although the binding of PB to human albumin has been studied, our knowledge of its binding to albumin from the other animal species is extremely limited. To address this issue, we characterized the binding of PB to albumin from several species (human, bovine, rabbit, and rat). The results indicated that PB interacts with 1 high-affinity site of albumin from these species, which corresponds to site II of human albumin. The affinities of PB to human and bovine albumins were higher than those to rabbit and rat albumin, and that to rabbit albumin was the lowest. Binding and molecular docking studies using structurally related compounds of PB suggested that species differences in the affinity are attributed to differences in the structural feature of the PB-binding sites on albumins (e.g., charge distribution, hydrophobicity, shape, or size).",
keywords = "albumin, distribution, molecular modeling, protein binding, protein structure",
author = "Keishi Yamasaki and Taisuke Enokida and Kazuaki Taguchi and Shigeyuki Miyamura and Akito Kawai and Shuichi Miyamoto and Toru Maruyama and Hakaru Seo and Masaki Otagiri",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.xphs.2017.04.025",
language = "English",
volume = "106",
pages = "2860--2867",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin

AU - Yamasaki, Keishi

AU - Enokida, Taisuke

AU - Taguchi, Kazuaki

AU - Miyamura, Shigeyuki

AU - Kawai, Akito

AU - Miyamoto, Shuichi

AU - Maruyama, Toru

AU - Seo, Hakaru

AU - Otagiri, Masaki

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Sodium 4-phenylbutyrate (PB) is clinically used as a drug for treating urea cycle disorders. Recent research has shown that PB also has other pharmacologic activities, suggesting that it has the potential for use as a drug for treating other disorders. In the process of drug development, preclinical testing using experimental animals is necessary to verify the efficacy and safety of PB. Although the binding of PB to human albumin has been studied, our knowledge of its binding to albumin from the other animal species is extremely limited. To address this issue, we characterized the binding of PB to albumin from several species (human, bovine, rabbit, and rat). The results indicated that PB interacts with 1 high-affinity site of albumin from these species, which corresponds to site II of human albumin. The affinities of PB to human and bovine albumins were higher than those to rabbit and rat albumin, and that to rabbit albumin was the lowest. Binding and molecular docking studies using structurally related compounds of PB suggested that species differences in the affinity are attributed to differences in the structural feature of the PB-binding sites on albumins (e.g., charge distribution, hydrophobicity, shape, or size).

AB - Sodium 4-phenylbutyrate (PB) is clinically used as a drug for treating urea cycle disorders. Recent research has shown that PB also has other pharmacologic activities, suggesting that it has the potential for use as a drug for treating other disorders. In the process of drug development, preclinical testing using experimental animals is necessary to verify the efficacy and safety of PB. Although the binding of PB to human albumin has been studied, our knowledge of its binding to albumin from the other animal species is extremely limited. To address this issue, we characterized the binding of PB to albumin from several species (human, bovine, rabbit, and rat). The results indicated that PB interacts with 1 high-affinity site of albumin from these species, which corresponds to site II of human albumin. The affinities of PB to human and bovine albumins were higher than those to rabbit and rat albumin, and that to rabbit albumin was the lowest. Binding and molecular docking studies using structurally related compounds of PB suggested that species differences in the affinity are attributed to differences in the structural feature of the PB-binding sites on albumins (e.g., charge distribution, hydrophobicity, shape, or size).

KW - albumin

KW - distribution

KW - molecular modeling

KW - protein binding

KW - protein structure

UR - http://www.scopus.com/inward/record.url?scp=85019671393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019671393&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2017.04.025

DO - 10.1016/j.xphs.2017.04.025

M3 - Article

VL - 106

SP - 2860

EP - 2867

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 9

ER -